Congratulations to one of our incubated startups, En Carta Diagnostics, for securing €1.5 million in pre-seed funding! 🎉

En Carta Diagnostics is a deeptech company developing rapid molecular diagnostic kits for Point-of-Care (POC) use. Their initial focus is on the early diagnosis of Lyme disease, which affects 1.2 million people annually.

Bravo to Guillaume Horréard, Margot Karlikow, PhD, and their entire team for this remarkable achievement! 👏